This approval was based on the phase 3 CodeBreaK 300 trial. CURE® recently spoke with the lead study investigator of the trial, Dr. Marwan G. Fakih, a Professor of Medical Oncology at City of Hope in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback